Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Determination Of Pd-l1 Expression In Circulating Tumor Cells Of Hypopharyngeal And Laryngeal Cancers And Correlation With Tissue Detection.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Determination Of Pd-l1 Expression In Circulating Tumor Cells Of Hypopharyngeal And Laryngeal Cancers And Correlation With Tissue Detection.

Related Experiment Video

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

Determination of PD-L1 Expression in Circulating Tumor Cells of Hypopharyngeal and Laryngeal Cancers and Correlation with Tissue Detection.

Chen Li1, Hongyu Zhu1, Qin Lin1

  • 1Department of Otolaryngology, Fujian Medical University Union Hospital, Fuzhou, China.

Anti-Cancer Agents in Medicinal Chemistry
|June 13, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

This study developed a sensitive method to detect Programmed Death-Ligand 1 (PD-L1) in circulating tumor cells (CTCs) from hypopharyngeal and laryngeal cancer patients. PD-L1 expression in CTCs correlates with tissue expression, aiding personalized cancer treatment strategies.

Keywords:
CTCsHypopharyngeal and laryngeal cancersPD-L1genomic mutations.

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.5K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K

Related Experiment Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.5K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Programmed Death-Ligand 1 (PD-L1) is a key immune checkpoint influencing cancer cell survival.
  • Understanding PD-L1 expression in circulating tumor cells (CTCs) is crucial for hypopharyngeal and laryngeal cancers (HLC).

Purpose of the Study:

  • To investigate the clinical significance of PD-L1 expression in CTCs from HLC patients.
  • To assess the consistency of PD-L1 expression between CTCs and tumor tissue.
  • To explore the preliminary clinical applications of CTC PD-L1 analysis.

Main Methods:

  • Developed immunolipid magnetic nano-beads for efficient CTC capture with minimal cytotoxicity.
  • Analyzed PD-L1 expression in CTCs from 38 HLC patients.
  • Correlated real-time CTC fluctuations with clinicopathological indices.
immunotherapy
tumorigenesis

Main Results:

  • The nano-bead system demonstrated high specificity and sensitivity for CTC capture.
  • PD-L1 expression consistency between CTCs and tissue exceeded 70%.
  • Inhibition of PD-L1 increased TNF-α and decreased IL-10 levels, indicating immune modulation.

Conclusions:

  • The developed CTC sorting system is effective for PD-L1 detection in HLC.
  • PD-L1 analysis in CTCs offers potential for guiding individualized cancer treatment strategies.